Verona Pharma
Biotechnology ResearchView the employees at
Verona Pharma-
Ostra Jewell, SPHR Sr Vice President, Human Resources at Verona Pharma
-
Durham
-
Top 10%
Catron Horton Experienced Corporate Consultant | Live & Virtual Events | Corporate Operations | Administration-
Wake Forest, North Carolina, United States
-
Rising Star
Leigh Ann Jordan Vice President, Compliance-
Raleigh, North Carolina, United States
-
Rising Star
Jaime Hilliard Senior Director, Market Research & Forecasting at Verona Pharma-
Raleigh-Durham-Chapel Hill Area
-
Rising Star
Latifa Benmassaoud Sr. Director Quality Assurance QA at Verona Pharma, Inc.-
Rising Star
Overview
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma's product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Ensifentrine met the primary endpoint in both ENHANCE-1 and ENHANCE-2 trials demonstrating statistically significant and clinically meaningful improvements in lung function. In addition, ensifentrine significantly reduced the rate of COPD exacerbations in ENHANCE-1 and ENHANCE-2. We are led by a management team with an established track record in the discovery, development and commercialization of respiratory therapies. Verona Pharma is listed on the Nasdaq Global Market in the United States under the ticker symbol VRNA. We are headquartered in London, UK, and have offices in Raleigh and Savannah in the US. For more information, please visit https://www.veronapharma.com.
-